Platinum-based chemotherapy for variant castrate-resistant prostate cancer - Abstract

PURPOSE: Clinical features characteristic of small-cell prostate carcinoma (SCPC), (""anaplastic"") often emerge during the progression of prostate cancer.

We sought to determine the efficacy of platinum-based chemotherapy in patients meeting at least one of seven prospectively defined "anaplastic" clinical criteria, including exclusive visceral or predominantly lytic bone metastases, bulky tumor masses, low PSA levels relative to tumor burden or short response to androgen deprivation therapy.

EXPERIMENTAL DESIGN: A 120-patient phase II trial of frontline carboplatin and docetaxel (CD) and second-line etoposide and cisplatin (EP) was designed to provide reliable clinical response estimates under a Bayesian probability model with early stopping rules in place for futility and toxicity.

RESULTS: Seventy-four of 113 (65.4%) and 24 of 71 (33.8%) were progression free after 4 cycles of CD and EP, respectively. Median overall survival (OS) was 16 months (95% CI, 13.6-19.0 months). Of the 7 "anaplastic" criteria, bulky tumor mass was significantly associated with poor outcome. Lactic acid dehydrogenase (LDH) strongly predicted for OS and rapid progression. Serum carcinoembryonic antigen (CEA) concentration strongly predicted OS but not rapid progression. Neuroendocrine markers did not predict outcome or response to therapy.

CONCLUSION: Our findings support the hypothesis that patients with "anaplastic" prostate cancer are a recognizable subset characterized by a high response rate of short duration to platinum-containing chemotherapies, similar to SCPC. Our results suggest that CEA is useful for selecting therapy in men with CRPC and consolidative therapies to bulky high-grade tumor masses should be considered in this patient population.

Written by:
Aparicio AM, Harzstark A, Corn PG, Wen S, Araujo J, Tu SM, Pagliaro L, Kim J, Millikan RE, Ryan CJ, Tannir NM, Zurita A, Mathew P, Arap W, Troncoso P, Thall P, Logothetis CJ.   Are you the author?
Genitourinary Medical Oncology, UT MD Anderson Cancer Center.

Reference: Clin Cancer Res. 2013 May 6. Epub ahead of print.
doi: 10.1158/1078-0432.CCR-12-3791


PubMed Abstract
PMID: 23649003

UroToday.com Prostate Cancer Section

 

 

 

 

 

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe